Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) EPS (Weighted Average and Diluted) (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.09 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 110.34% to -$0.09 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.48 through Dec 2025, up 58.97% year-over-year, with the annual reading at -$0.49 for FY2025, 57.76% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.09 at Inhibikase Therapeutics, up from -$0.13 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.87 in Q4 2024, with the low at -$1.1 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.47, with a median of -$0.65 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 488.89% in 2022, then skyrocketed 227.94% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.2 in 2021, then plummeted by 410.0% to -$1.02 in 2022, then surged by 33.33% to -$0.68 in 2023, then skyrocketed by 227.94% to $0.87 in 2024, then plummeted by 110.34% to -$0.09 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.09, -$0.13, and -$0.11 for Q4 2025, Q3 2025, and Q2 2025 respectively.